Beyond
Advisory
Treehill Partners
Focused on Transactions and Transitions in Healthcare
International strategic and financial advisory focused exclusively on healthcare. Hand-picked team of successful senior professionals.
Diverse backgrounds across banking & finance, strategic consulting and leadership roles in industry
What We Do
Value maximization at each point along the value creation life cycle
Unique Edge
Enabled by the seniority and pedigree of our team
we answer the most intricate questions
What is the Situation?
Independent
Assessment
Assessment
Where to go from here?
Understand and
Increase Optionality
Increase Optionality
How will things play out?
Inform Today’s
Decision Making
Decision Making
Biotech Restructuring
At Treehill Partners, we recognize the unique challenges currently encountered by the biotech sector.
As public equity markets have pivoted away from high-risk stocks, organizations across the biotech sector are experiencing a scarcity of funding.
This shift necessitates a strategic reconfiguration of product development priorities and activities – a process we refer to as biotech restructuring.
Understanding how essential this restructuring process is, we offer comprehensive guidance and expertise in this area.
Our Capabilities
Strategic Reprioritization
Reassess product development pipelines, strategizing on resource allocation and the corporate development pathways arising therefrom.
Operational Restructuring
Revisit operational models to align with financial realities and revised strategic priorities.
Financial Advisory
Preeminent corporate finance advice and execution to address biotech fundability and transactability challenges.
Operational Restructuring
Evolve equity stories in a congruent yet transformative manner.
Long Term Strategic Planning
Plant seeds for growth and sustainable corporate evolution, developing novel business models for the biotech of tomorrow.
At Treehill Partners, we firmly believe in biotech’s potential and its necessity in solving some of the world’s most pressing health issues. In these challenging times for the sector, our commitment is to stand by your side, offering a personalized, hands-on approach to ensure your organization can sail these rough waters and emerge stronger on the other side.
To learn more about how Treehill Partners can help guide your biotech company through a successful restructuring process, contact us today.
What Clients
Say About Us
US Pharma C-suite
“Had a great experience with this team back at Blackstone. At Treehill, they had an even more personalized approach and could really engage on the objectives that were important to me”
US Biotech CSO
“It is rare to come across a transaction advisory firm with the depth of scientific and medical knowledge Treehill has”
US Biotech CEO
“With the opportunity to pivot into Covid-19, Treehill got involved to write our clinical protocol, prepared us for a multi-agency TechWatch meeting and supported all efforts to submit the IND”
US CRO C-suite
“Their depth of insight made Treehill the by far the most suitable sell-side team that we interviewed”
EU Biotech CEO
“Their familiarity with the large caps enabled our team to gain confidence to reach for goals beyond expectations. Formidable negotiators”
EU Medtech CBO
“It is very different being advised by people who know exactly what you are going through”
EU VC
“Treehill was focused on identifying the solution to address our objectives from day 1”
EU Pharma BD
“As comfortable dealing with scientific, medical and regulatory matters as they are with transaction structuring”
US Biotech CEO
“As a first time CEO it was invaluable to have access to their many decades of CEO decision making experience. I was glad to have Treehill in my corner”
US Private Equity
“Really straight talking, honest and focused. If you want direct answers these are the right team”
EU Pharma Corp.Dev.
“Treehill got on top of the situation immediately, clearly identifying the key issues and outlining the roadmap for us to follow together”
EU Medtech COO
“Despite their seniority and broad experiences, the Treehill team were easy to talk to and integrated with our team very easily”
US Biotech CBO
“Treehill brought to the table a well-coordinated and motivated team of complimentary capabilities to support our path towards success”
US Biotech CEO
“Treehill’s ability to advise on the large-cap to small-cap dynamic was uniquely helpful to us during this crucial transition”
EU Biotech CEO
“Treehill complemented our negotiation team with a fair perspective but challenging us to be more courageous when needed”
The above testimonial may not be representative of the experience of other clients and should not be construed as a guarantee of future performance or success.
The above testimonial may not be representative of the experience of other clients and should not be construed as a guarantee of future performance or success.
Case Studies
The above testimonial may not be representative of the experience of other clients and should not be construed as a guarantee of future performance or success.
The above testimonial may not be representative of the experience of other clients and should not be construed as a guarantee of future performance or success.